title: Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention.
abstract: Sharing of pre-exposure prophylaxis (PrEP) medications is a concern for PrEP implementation. For HIV-1 serodiscordant couples, sharing may undermine the HIV-1 prevention benefit and also cause antiretroviral resistance if taken by HIV-1 infected partners. Within a PrEP efficacy trial among HIV-1 serodiscordant couples, we assessed the occurrence of PrEP sharing by self-report and plasma tenofovir concentrations in HIV-1 infected partners. PrEP sharing was self-reported at <0.01% of visits, and 0%-1.6% of randomly selected and 0% of purposively selected specimens from HIV-1 infected participants had detectable tenofovir concentrations (median: 66.5 ng/mL, range: 1.3-292 ng/mL). PrEP sharing within HIV-1 serodiscordant couples was extremely rare.
authors.affiliation: *Department of Epidemiology, University of Washington, Seattle, WA; †Center for Global Health and Department of Medicine, Massachusetts General Hospital, Boston, MA; ‡Departments of Pathology and Medicine, Johns Hopkins University, Baltimore, MD; §Department of Epidemiology and Biostatistics, Makerere University, Kampala, Uganda; ‖Division of Clinical Pharmacology and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ¶Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA; #Department of Global Health, University of Washington, Seattle, WA; **Department of Medicine, University of Manitoba, Winnipeg, Canada; ††Oregon Health and Sciences University and Portland State University School of Public Health, Portland, OR; and ‡‡Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA.
authors.forename: Kerry A
authors.initials: KA
authors.lastname: Thomson
authors.forename: Jessica E
authors.initials: JE
authors.lastname: Haberer
authors.forename: Mark A
authors.initials: MA
authors.lastname: Marzinke
authors.forename: Andrew
authors.initials: A
authors.lastname: Mujugira
authors.forename: Craig W
authors.initials: CW
authors.lastname: Hendrix
authors.forename: Connie
authors.initials: C
authors.lastname: Celum
authors.forename: Patrick
authors.initials: P
authors.lastname: Ndase
authors.forename: Allan
authors.initials: A
authors.lastname: Ronald
authors.forename: David R
authors.initials: DR
authors.lastname: Bangsberg
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
mesh_terms: D019380:Anti-HIV Agents; D044383:Black People; D005191:Family Characteristics; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D018023:HIV Seronegativity / Q000187:drug effects*; D006679:HIV Seropositivity / Q000635:transmission*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007630:Kenya / Q000453:epidemiology; D008297:Male; D065129:Pre-Exposure Prophylaxis; D063487:Prescription Drug Misuse / Q000706:statistics & numerical data*; D012309:Risk-Taking; D014454:Uganda / Q000453:epidemiology; D016903:Drug Monitoring
chemical_list: D019380:Anti-HIV Agents